Icatibant in viral infections
暂无分享,去创建一个
[1] X. Solanich,et al. Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial , 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] A. Sjödin,et al. Clinical and genomic characterisation of a fatal Puumala orthohantavirus case with low levels of neutralising antibodies , 2022, Infectious diseases.
[3] A. Vaheri,et al. Neutralizing Antibody Titers in Hospitalized Patients with Acute Puumala Orthohantavirus Infection Do Not Associate with Disease Severity , 2022, Viruses.
[4] A. Vaheri,et al. Severe Puumala virus infection in a patient with a lymphoproliferative disease treated with icatibant , 2015, Infectious diseases.
[5] S. Meri,et al. Pathophysiology of a severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. , 2014, Antiviral research.
[6] A. Vaheri,et al. Uncovering the mysteries of hantavirus infections , 2013, Nature Reviews Microbiology.
[7] Shannon L. Taylor,et al. Endothelial Cell Permeability during Hantavirus Infection Involves Factor XII-Dependent Increased Activation of the Kallikrein-Kinin System , 2013, PLoS pathogens.
[8] J. Tenhunen,et al. A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant , 2013, Scandinavian journal of infectious diseases.
[9] B. Hellerstedt,et al. Postsplenectomy cytomegalovirus mononucleosis is a distinct clinicopathologic syndrome. , 2010, The American journal of the medical sciences.
[10] J. Mustonen,et al. Pulmonary involvement in nephropathia epidemica: radiological findings and their clinical correlations. , 1996, Clinical nephrology.